Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CSL Biotherapies, a subsidiary of one of the manufacturers of influenza vaccine, has started shipment of its influenza virus vaccine in the US for the 2008-2009 season.
Subscribe to our email newsletter
CSL plans to deliver more than six million doses of Afluria and the majority of the supply will be in single-dose, thimerosal-free, pre-filled syringes.
Afluria is indicated for the active immunization of persons aged 18 years and older against influenza caused by influenza virus subtypes A and type B present in the vaccine. The indication is based on the immune response elicited by Afluria; no controlled clinical studies have demonstrated a decrease in influenza disease after vaccination with Afluria.
Paul Perreault, executive vice president of worldwide commercial operations at CSL Biotherapies, said: “CSL’s mission is to protect lives through vaccination, so we will continue to support educational and community efforts to increase vaccination rates in priority and at-risk US populations, such as healthcare workers, pregnant women and college students.”